Predicting the response to neoadjuvant chemotherapy in gastric cancer / 国际外科学杂志

Randomized trials have demonstrated a benefit from neoadjuvant chemotherapy in gastric cancer.However the optimal approach in individual patients is not clear.There are differences in the chemical drug sensitivities of individual patients.This scenario demands the development of methods to predict response to neoadjuvant therapy.This paper reviews the relevant research progress.Published results are as follows:histological characteristics and histopathological response corelate with survival,traditional imaging needs improvement and integration to increase the accuracy,while PET holds advantage in early selection of patients without response,and existing candidate biomarkers need to bc properly qualified.